Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience

Encorafenib plus cetuximab with or without binimetinib showed increased objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared with chemotherapy plus anti-EGFR in previously treated patients with BRAF V600E-mutated (mut) metastatic colorectal cancer (mCRC)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	ESMO open 2022-06, Vol.7 (3), p.100506, Article 100506
Hauptverfasser:	Boccaccino, A., Borelli, B., Intini, R., Antista, M., Bensi, M., Rossini, D., Passardi, A., Tamberi, S., Giampieri, R., Antonuzzo, L., Noto, L., Roviello, G., Zichi, C., Salati, M., Puccini, A., Noto, C., Parisi, A., Rihawi, K., Persano, M., Crespi, V., Libertini, M., Giordano, M., Moretto, R., Lonardi, S., Cremolini, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	adjusted MAF Antineoplastic Combined Chemotherapy Protocols - adverse effects BEACON trial Benzimidazoles binimetinib BRAF V600E mutation Carbamates Cetuximab - adverse effects Colonic Neoplasms - drug therapy Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics encorafenib Humans Original Research Proto-Oncogene Proteins B-raf - genetics real-life studies Sulfonamides
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!